Back to Browse Journals » Drug, Healthcare and Patient Safety » Volume 3

Monoamine depletion by reuptake inhibitors

Authors Hinz M, Stein A, Uncini T

Published 20 October 2011 Volume 2011:3 Pages 69—77

DOI https://doi.org/10.2147/DHPS.S24798

Review by Single-blind

Peer reviewer comments 4

Marty Hinz1, Alvin Stein2, Thomas Uncini3
1Clinical Research, NeuroResearch Clinics Inc, Cape Coral, FL; 2Stein Orthopedic Associates, Plantation, FL; 3DBS Labs Inc, Duluth, MN, USA

Background: Disagreement exists regarding the etiology of cessation of the observed clinical results with administration of reuptake inhibitors. Traditionally, when drug effects wane, it is known as tachyphylaxis. With reuptake inhibitors, the placebo effect is significantly greater than the drug effect in the treatment of depression and attention deficit hyperactivity disorder, leading some to assert that waning of drug effects is placebo relapse, not tachyphylaxis.
Methods: Two groups were retrospectively evaluated. Group 1 was composed of subjects with depression and Group 2 was composed of bariatric subjects treated with reuptake inhibitors for appetite suppression.
Results: In Group 1, 200 subjects with depression were treated with citalopram 20 mg per day. A total of 46.5% (n = 93) achieved relief of symptoms (Hamilton-D rating score ≤ 7), of whom 37 (39.8%) of whom experienced recurrence of depression symptoms, at which point an amino acid precursor formula was started. Within 1–5 days, 97.3% (n = 36) experienced relief of depression symptoms. In Group 2, 220 subjects were treated with phentermine 30 mg in the morning and citalopram 20 mg at 4 pm. In this group, 90.0% (n = 198) achieved adequate appetite suppression. The appetite suppression ceased in all 198 subjects within 4–48 days. Administration of an amino acid precursor formula restored appetite suppression in 98.5% (n = 195) of subjects within 1–5 days.
Conclusion: Reuptake inhibitors do not increase the total number of monoamine molecules in the central nervous system. Their mechanism of action facilitates redistribution of monoamines from one place to another. In the process, conditions are induced that facilitate depletion of monoamines. The "reuptake inhibitor monoamine depletion theory" of this paper offers a novel and unified explanation for the waning of response seen after a reuptake inhibitor is started, independent of a drug or placebo etiology.

Keywords: reuptake inhibitor, depletion, tachyphylaxis, relapse, serotonin, dopamine

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Parkinson's disease managing reversible neurodegeneration [Corrigendum]

Hinz M, Stein A, Cole T, McDougall B, Westaway M

Neuropsychiatric Disease and Treatment 2016, 12:1587-1588

Published Date: 28 June 2016

Amino acid management of Parkinson's disease: a case study [Corrigendum]

Hinz M, Stein A, Uncini T

International Journal of General Medicine 2016, 9:205-206

Published Date: 13 June 2016

Parkinson’s disease managing reversible neurodegeneration

Hinz M, Stein A, Cole T, McDougall B, Westaway M

Neuropsychiatric Disease and Treatment 2016, 12:763-775

Published Date: 5 April 2016

Parkinson’s disease-associated melanin steal

Hinz M, Stein A, Cole T

Neuropsychiatric Disease and Treatment 2014, 10:2331-2337

Published Date: 10 December 2014

Parkinson's disease: carbidopa, nausea, and dyskinesia

Hinz M, Stein A, Cole T

Clinical Pharmacology: Advances and Applications 2014, 6:189-194

Published Date: 14 November 2014

The Parkinson's disease death rate: carbidopa and vitamin B6

Hinz M, Stein A, Cole T

Clinical Pharmacology: Advances and Applications 2014, 6:161-169

Published Date: 21 October 2014

Management of L-dopa overdose in the competitive inhibition state

Hinz M, Stein A, Cole T

Drug, Healthcare and Patient Safety 2014, 6:93-99

Published Date: 22 July 2014

5-HTP efficacy and contraindications

Hinz M, Stein A, Uncini T

Neuropsychiatric Disease and Treatment 2012, 8:323-328

Published Date: 19 July 2012

Relative nutritional deficiencies associated with centrally acting monoamines

Hinz M, Stein A, Uncini T

International Journal of General Medicine 2012, 5:413-430

Published Date: 8 May 2012

The discrediting of the monoamine hypothesis

Hinz M, Stein A, Uncini T

International Journal of General Medicine 2012, 5:135-142

Published Date: 14 February 2012

APRESS: apical regulatory super system, serotonin, and dopamine interaction

Hinz M, Stein A, Uncini T

Neuropsychiatric Disease and Treatment 2011, 7:457-463

Published Date: 5 August 2011

Amino acid management of Parkinson’s disease: a case study

Marty Hinz, Alvin Stein, Thomas Uncini

International Journal of General Medicine 2011, 4:165-174

Published Date: 28 February 2011

Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine

Marty Hinz, Alvin Stein, Thomas Uncini

Research and Reports in Urology 2011, 3:19-24

Published Date: 4 February 2011

Amino acid-responsive Crohn's disease: a case study

Alvin Stein, Marty Hinz, Thomas Uncini

Clinical and Experimental Gastroenterology 2010, 3:171-177

Published Date: 6 December 2010

A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole

Marty Hinz, Alvin Stein, Thomas Uncini

Neuropsychiatric Disease and Treatment 2010, 6:741-747

Published Date: 9 November 2010

Neurotransmitter testing of the urine: a comprehensive analysis

Marty Hinz, Alvin Stein, George Trachte, et al

Research and Reports in Urology 2010, 2:177-183

Published Date: 7 October 2010

The dual-gate lumen model of renal monoamine transport

Marty Hinz, Alvin Stein, Thomas Uncini

Neuropsychiatric Disease and Treatment 2010, 6:387-392

Published Date: 5 July 2010

Readers of this article also read:

Safety and comfort evaluation of a new formulation of Visine® lubricant eye drops containing HydroBlend™ and GentlePur™

Torkildsen G, Frisch S, Bai M, Gentner III L, Doshi U, Zhang J

Clinical Ophthalmology 2016, 10:331-336

Published Date: 19 February 2016

Microneedling dilates the follicular infundibulum and increases transfollicular absorption of liposomal sepia melanin

Serrano G, Almudéver P, Serrano JM, Cortijo J, Faus C, Reyes M, Expósito I, Torrens A, Millán F

Clinical, Cosmetic and Investigational Dermatology 2015, 8:313-318

Published Date: 26 June 2015

Parkinson's disease: carbidopa, nausea, and dyskinesia

Hinz M, Stein A, Cole T

Clinical Pharmacology: Advances and Applications 2014, 6:189-194

Published Date: 14 November 2014

Relative nutritional deficiencies associated with centrally acting monoamines

Hinz M, Stein A, Uncini T

International Journal of General Medicine 2012, 5:413-430

Published Date: 8 May 2012

A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole

Marty Hinz, Alvin Stein, Thomas Uncini

Neuropsychiatric Disease and Treatment 2010, 6:741-747

Published Date: 9 November 2010

Efficacy of hand held, inexpensive UV light sources on Acanthamoeba, causative organism in amoebic keratitis

Ivan Cometa, Andrew Rogerson, Scott Schatz

Clinical Optometry 2010, 2:9-15

Published Date: 21 January 2010